KLRS NASDAQ
Kalaris Therapeutics Inc
1W: -1.9%
1M: -19.1%
3M: -48.8%
YTD: -38.3%
1Y: +53.8%
$4.92
-0.20 (-3.91%)
Weekly Expected Move ±8.5%
$4
$4
$5
$5
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$6.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$92.0M
52W Range2.14-11.88
Volume86,930
Avg Volume77,337
Beta0.15
Dividend—
Analyst Ratings
Company Info
CEOAndrew Oxtoby
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2020-07-30
Websitekalaristx.com
139 Main Street, Suite 500
Cambridge, MA 02142
US
Cambridge, MA 02142
US
+1 610 550 4220
About Kalaris Therapeutics Inc
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Latest News
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts
Kalaris Therapeutics (NASDAQ:KLRS) Stock Price Down 3.6% – What’s Next?
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Kalaris Therapeutics, Inc. GAAP EPS of -$2.85
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | P-Purchase | 244,300 | $4.83 | 2026-05-20 |
| AKKARAJU SRINIVAS | J-Other | 66,906 | — | 2026-05-20 |
| AKKARAJU SRINIVAS | J-Other | 14,937 | — | 2026-05-20 |
| AKKARAJU SRINIVAS | J-Other | 4,471 | — | 2026-05-20 |
| Hagen Brett R | S-Sale | 1,915 | $6.72 | 2026-03-20 |